Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PUBLICATIONS - Health service directory entitled KompetansemiljXer i Helsetjenesten 1995:

This article was originally published in Clinica

Executive Summary

Norway's state health inspectorate (SHT) has published a new health service directory entitled Kompetansemiljoer i Helsetjenesten 1995. The 215-page reference work provides a systematic and detailed overview of 366 institutions engaged in R&D work relevant to the health sector, including medicinal faculties and institutes, and public departments and institutions. It also lists patient organisations, specialist health libraries, etc. Further details are available from: Helge Iversen, Informasjonssjef, Statens Helsetilsyn, Pb 8128 Dep, 0032 Oslo, Norway. Tel: +47 2234 8808. Fax: +47 2234 2767.

You may also be interested in...



USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

Momenta Pays Out On Enoxaparin Shut-Out

Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.

Topics

UsernamePublicRestriction

Register

MT092049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel